Fig. 5: Deguelin, the PI3K-AKT inhibitor, reverses TGM3 knockdown-induced tumor growth cSCC in vivo. | Cell Death & Disease

Fig. 5: Deguelin, the PI3K-AKT inhibitor, reverses TGM3 knockdown-induced tumor growth cSCC in vivo.

From: Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated Keratin 14 degradation

Fig. 5

A, B Deguelin treatment reversed TGM3 knockdown-induced tumor growth in subcutaneous xenograft tumor model. A, B Quantification of tumor weight (A) and tumor volume (B) for each group. n = 5. C Representative IHC staining density of TGM3, AKT phosphorylation (Ser473) and KRT14 in subcutaneous tumor. Scale bar, 100 μm. D Deguelin reversed TGM3 knockdown-induced PI3K-AKT activation and EMT progression in subcutaneous xenograft tumor models. n = 5. Results were expressed as mean ± SD; n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001; Welch’s test (A); Two-way ANOVA Sidak test (B); Mann–Whitney (D).

Back to article page